By enabling more targeted and safer therapies, CRISPR genome editing is emerging as a powerful tool to address these issues.<h4>Methods</h4>We review current literature on CRISPR technologies in leukaemia immunotherapy, focussing on studies involving four key antigens commonly targeted in leukaemia: CD33, CD7, CD45 and CD19.<h4>Results</h4>We trace the evolution of CRISPR technologies from conventional CRISPR-Cas9 to base editing, highlighting how CRISPR platforms are being repurposed to enhance efficacy and clinical safety. This evidence concerns the gene PTPRC and leukemia.